GlassScriptPhysician profile
George Varughese
NPI 1154585149
$720.76
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $668 · 2020: $32.83 · 2021: $19.79.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $172.55 | 2019 | |
| Gilead Sciences, INC. | $111.78 | 2019 | |
| Amgen INC. | $57.75 | 2019 | |
| Janssen Pharmaceuticals, INC | $57.19 | 2019 | |
| Novartis Pharmaceuticals Corporation | $56.44 | 2019 | |
| Novo Nordisk INC | $49.13 | 2019-2021 | |
| Shire North American Group INC | $36.67 | 2019 | |
| Allergan, INC. | $33.51 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.43 | 2019 | |
| Mylan Specialty L.P. | $24.56 | 2019 | |
| Avanir Pharmaceuticals, INC. | $14.93 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.70 | 2020 | |
| Insulet Corporation | $14.57 | 2019 | |
| Insmed, INC. | $14.47 | 2019 | |
| Amarin Pharma, INC. | $13.88 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $11.11 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.09 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Varughese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.